MX2021009842A - Células madre de donantes universales y métodos relacionados. - Google Patents

Células madre de donantes universales y métodos relacionados.

Info

Publication number
MX2021009842A
MX2021009842A MX2021009842A MX2021009842A MX2021009842A MX 2021009842 A MX2021009842 A MX 2021009842A MX 2021009842 A MX2021009842 A MX 2021009842A MX 2021009842 A MX2021009842 A MX 2021009842A MX 2021009842 A MX2021009842 A MX 2021009842A
Authority
MX
Mexico
Prior art keywords
stem cells
universal donor
donor stem
related methods
disclosed
Prior art date
Application number
MX2021009842A
Other languages
English (en)
Inventor
Torsten B Meissner
Chad A Cowan
Leonardo M R Ferreira
Jack L Strominger
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2021009842A publication Critical patent/MX2021009842A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se describen células madre de donantes universales y métodos relacionados para su uso y producción. Las células madre de donantes universales descritas en la presente son útiles para superar el rechazo inmunitario en las terapias de trasplante celular. En determinadas modalidades, las células madre de donantes universales descritas en la presente tienen una expresión modulada de uno o más antígenos leucocitarios humanos del MHC-I y MHC-II y uno o más factores tolerogénicos.
MX2021009842A 2019-02-15 2020-02-16 Células madre de donantes universales y métodos relacionados. MX2021009842A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201916277913A 2019-02-15 2019-02-15
US201916596697A 2019-10-08 2019-10-08
PCT/US2020/018467 WO2020168317A2 (en) 2019-02-15 2020-02-16 Universal donor stem cells and related methods

Publications (1)

Publication Number Publication Date
MX2021009842A true MX2021009842A (es) 2021-12-10

Family

ID=72045137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009842A MX2021009842A (es) 2019-02-15 2020-02-16 Células madre de donantes universales y métodos relacionados.

Country Status (11)

Country Link
EP (1) EP3924375A4 (es)
JP (1) JP2022526218A (es)
KR (1) KR20210128440A (es)
CN (1) CN113906048A (es)
AU (1) AU2020223192A1 (es)
BR (1) BR112021016178A2 (es)
CA (1) CA3130398A1 (es)
IL (1) IL285619A (es)
MX (1) MX2021009842A (es)
SG (1) SG11202108891QA (es)
WO (1) WO2020168317A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021231712A1 (en) * 2020-05-15 2021-11-18 Rxcell Inc. Hypoimmunogenic cells and uses thereof in immune responses
CN114457021A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd47抗体的多能干细胞及其衍生物与应用
CN114525256A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用
WO2022113056A1 (en) 2020-11-30 2022-06-02 Crispr Therapeutics Ag Gene-edited natural killer cells
KR20230130635A (ko) * 2020-12-11 2023-09-12 인텔리아 테라퓨틱스, 인크. 세포에서 mhc 클래스 ii를 감소시키기 위한 조성물및 방법
CA3205042A1 (en) * 2020-12-23 2022-06-30 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying ciita in a cell
EP4271404A2 (en) 2020-12-31 2023-11-08 Sana Biotechnology, Inc. Methods and compositions for modulating car-t activity
IL308097A (en) 2021-05-27 2023-12-01 Sana Biotechnology Inc Hypoimmunogenic cells that include transgenic HLA-E or HLA-G
CA3227613A1 (en) 2021-08-11 2023-02-16 William Dowdle Inducible systems for altering gene expression in hypoimmunogenic cells
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023191063A1 (ja) * 2022-04-01 2023-10-05 株式会社Logomix 遺伝子工学、細胞工学、および細胞医薬に適した細胞およびその製造方法
WO2024003349A1 (en) 2022-07-01 2024-01-04 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515139A (ja) * 2015-05-08 2018-06-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 万能ドナー幹細胞および関連する方法
CA3003150A1 (en) * 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
BR112019014257A2 (pt) * 2017-01-13 2020-04-28 Univ California método para gerar uma célula-tronco pluripotente hipoimunogênica, célula-tronco pluripotente hipoimunogênica humana, método para produzir uma célula pluripotente hipoimunogênica, e ss-2 microglobulina

Also Published As

Publication number Publication date
EP3924375A4 (en) 2023-03-22
AU2020223192A1 (en) 2021-09-09
WO2020168317A3 (en) 2020-10-29
CN113906048A (zh) 2022-01-07
EP3924375A2 (en) 2021-12-22
SG11202108891QA (en) 2021-09-29
CA3130398A1 (en) 2020-08-20
BR112021016178A2 (pt) 2021-11-03
JP2022526218A (ja) 2022-05-24
WO2020168317A8 (en) 2021-02-25
KR20210128440A (ko) 2021-10-26
WO2020168317A2 (en) 2020-08-20
IL285619A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2021009842A (es) Células madre de donantes universales y métodos relacionados.
WO2016183041A3 (en) Universal donor stem cells and related methods
WO2019014351A3 (en) Universal donor cells and related methods
PH12021550476A1 (en) Universal donor cells
CY1123730T1 (el) Εμφυτευση βλαστικων κυτταρων με εναν συνδυασμο ενος παραγοντα που στοχευει βλαστικα κυτταρα και ρυθμιση ανοσορυθμιστικης σηματοδοτησης
MX2020006688A (es) Celulas presentadoras de antigenos artificiales y metodos de uso.
MX2021000607A (es) Células t con receptor de antígeno quimérico derivadas de células madre pluripotentes inmunomodificadas.
AU2019205319A8 (en) Heart valve prosthesis and delivery
MX2021002415A (es) Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas.
MX2019008413A (es) Celulas pluripotentes inmunodiseñadas.
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
MX2022002663A (es) Celulas donantes universales.
MX2022002783A (es) Celulas donantes universales.
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
MX2021008142A (es) Metodos para cosechar cultivos de celulas de mamifero.
WO2017160717A3 (en) Method of treating diseases using kinase modulators
MX2021013355A (es) Composiciones de proteínas de fusión quiméricas modificadas y métodos de uso de las mismas.
MX2019012017A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
EP4269566A3 (en) Genetic markers for engraftment of human cardiac ventricular progenitor cells
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
WO2018009528A8 (en) Combination cancer immunotherapies with arginine depletion agents
AU2018338423A1 (en) Novel anti-HLA-A2 antibodies and uses thereof
MX2021006393A (es) Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa